Oncotype DX Breast Recurrence Score
Commercial- Indications
- Breast cancer
Company intelligence / Profile preview
Genomic Health
Redwood City, California, United Statesexactsciences.com ↗
- Ownership
- Private
- Employees
- ~900
- Development stage
- Other
01
Overview
Genomic Health's Oncotype DX assays are clinically validated, globally adopted genomic tests used for risk stratification and treatment selection in breast, colon, and prostate cancer. Over one million patients have benefited from these tests, which are incorporated into major guidelines worldwide[3][1][5].
- Therapeutic areas
- Oncology
- Modalities
- Molecular diagnostic assayGenomic assayGene expression signature
- Industry
- Molecular Diagnostics
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Exact Sciences (acquirer/strategic partner)
Beyond the preview
Go deeper on Genomic Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genomic Health.